Ncardia

Ncardia company information, Employees & Contact Information

Explore related pages

Related company profiles:

Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications. Explore our website to learn more www.ncardia.com.

Company Details

Employees
52
Founded
-
Address
Ncardia Leiden, Galileiweg 8, Building Biopartner 1,netherlands
Phone
(310) 713-3222
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Leiden, South Holland
Looking for a particular Ncardia employee's phone or email?

Ncardia Questions

News

Ncardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision Medicine - Business Wire

Ncardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision Medicine Business Wire

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research - DutchNews.nl

Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research DutchNews.nl

Ncardia - Drug Target Review

Ncardia Drug Target Review

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today - BioInformant

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today BioInformant

Ncardia Expands iPSC Manufacturing and Phenotypic Drug Discovery Services With Support From Investors - PR Newswire

Ncardia Expands iPSC Manufacturing and Phenotypic Drug Discovery Services With Support From Investors PR Newswire

iPSC technology company Ncardia receives US$60 million investment - RegMedNet

iPSC technology company Ncardia receives US$60 million investment RegMedNet

Ncardia inks $60M funding deal to expand discovery and commercial production services for stem cells - Fierce Biotech

Ncardia inks $60M funding deal to expand discovery and commercial production services for stem cells Fierce Biotech

iPSC-derived microglia may help advance ALS research, therapies - ALS News Today

iPSC-derived microglia may help advance ALS research, therapies ALS News Today

Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings - Business Wire

Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings Business Wire

Ncardia launches Cellistic for iPSC cell therapy production - The Science Advisory Board

Ncardia launches Cellistic for iPSC cell therapy production The Science Advisory Board

Ncardia secures more than $60 million to enhance and expand leading iPSC offerings - Drug Target Review

Ncardia secures more than $60 million to enhance and expand leading iPSC offerings Drug Target Review

Ncardia announces completion of €10.5M Investment Round - Innovationquarter

Ncardia announces completion of €10.5M Investment Round Innovationquarter

On back of Roche pact, newly formed Ncardia wins iPSC deal with Evotec - Fierce Biotech

On back of Roche pact, newly formed Ncardia wins iPSC deal with Evotec Fierce Biotech

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes - Business Wire

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes Business Wire

NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions - BioInformant

NCardia, a Global Force in hiPSC Drug Discovery and Development Products and Solutions BioInformant

Ncardia appoints Andy Holt as Chief Commercial Officer - Drug Target Review

Ncardia appoints Andy Holt as Chief Commercial Officer Drug Target Review

Advancing the Future of Cardiac Safety - Fierce Biotech

Advancing the Future of Cardiac Safety Fierce Biotech

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction - Business Wire

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction Business Wire

Ncardia Established Following Pluriomics Axiogenesis Merger - Innovationquarter

Ncardia Established Following Pluriomics Axiogenesis Merger Innovationquarter

10 fastest growing biotech startups in Leiden - Silicon Canals

10 fastest growing biotech startups in Leiden Silicon Canals

Top Ncardia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant